This article is more than 5 years old. Information may no longer be current.
Integrated EVAR System Available for Treatment of Abdominal Aortic Aneurysms
Click Here to Manage Email Alerts
Endologix announced that the FDA has approved a bifurcated endograft system for the treatment of abdominal aortic aneurysms, according to a press release.
The AFX2 Bifurcated Endograft System (Endologix Inc.) is intended to reduce the number of procedure steps needed for delivery and deployment of the endograft and facilitates percutaneous endovascular aneurysm repair (EVAR) by providing low-profile, contralateral access through a 7F introducer, according to the release.
The integrated EVAR system combines the company’s ActiveSeal technology, expanded polytetrafluoroethylene graft material (DuraPly) and a proximal endograft (VELA).
“With the approval of AFX2, we have taken a versatile platform and combined it with an easy-to-use, low-profile delivery system,” John McDermott, CEO of Endologix, said in the release. “We believe this will enable more physicians to utilize AFX2 and offer its unique clinical benefits to patients.”
The company anticipates a commercial launch in the United States during early 2016, according to the release.
Disclosure: McDermott is an employee of Endologix.